Skip to content
Clinical Trials – home

Protein C: A Vital Treatment for Blood Clotting Disorders and Sepsis

3 / 4
trials open to patients / all trials
13+
Countries

In short

Protein C, a naturally occurring anticoagulant in the human body, has been the subject of several clinical trials aimed at exploring its therapeutic potential in various medical conditions. These trials have investigated the use of Protein C concentrates and activated forms in treating conditions such as congenital Protein C deficiency, sepsis, acute pancreatitis, and stroke. The studies have focused on evaluating the safety, efficacy, and optimal dosing of Protein C-based treatments, with the goal of improving patient outcomes in these challenging medical scenarios.

At a glance

Conditions Studied
Congenital Protein C Deficiency, Sepsis, Septic Shock, Acute Pancreatitis, Acute Ischemic Stroke
Forms of Protein C Used
Protein C Concentrate, Activated Protein C
Administration Methods
Intravenous injection, Continuous infusion
Primary Outcomes Measured
Safety (adverse events, bleeding), Efficacy in treating specific conditions, Changes in organ function, Mortality rates
Secondary Outcomes
Length of hospital stay, Improvements in condition-specific symptoms, Changes in microcirculation, Functional recovery scores
Safety Concerns
Risk of bleeding, particularly intracranial hemorrhage
Potential Benefits
Improved treatment of Protein C deficiency, Reduced organ dysfunction in sepsis, Potential neuroprotection in stroke

What is Protein C?

Protein C is a naturally occurring protein in our blood that plays a crucial role in preventing excessive blood clotting and reducing inflammation. When there's a deficiency or malfunction of this protein, it can lead to serious health issues. To address this, medical researchers have developed a treatment called Protein C concentrate.

This treatment is available in different forms, including:

  • Freeze-dried Human Protein C Concentrate (also known as TAK-662)
  • Protein C Concentrate (Human) Vapor Heated
  • Activated Protein C (APC)

Conditions Treated with Protein C

Protein C concentrate is used to treat several serious medical conditions, including:

  1. Congenital Protein C Deficiency: This is a rare inherited disorder where the body doesn't produce enough Protein C, leading to an increased risk of blood clots.
  2. Sepsis and Septic Shock: These are life-threatening conditions caused by the body's extreme response to an infection, often leading to organ failure.
  3. Purpura Fulminans: A rare, severe blood clotting disorder that can cause skin necrosis (death of skin tissue).
  4. Coumarin-induced Skin Necrosis: A rare complication of anticoagulant therapy.
  5. Acute Pancreatitis: Severe inflammation of the pancreas.
  6. Acute Ischemic Stroke: A type of stroke caused by a blood clot blocking blood flow to the brain.

How Protein C Works

Protein C plays a dual role in the body:

  1. Anticoagulant: It helps prevent excessive blood clotting by regulating other proteins involved in the clotting process.
  2. Anti-inflammatory: It helps reduce inflammation, which is particularly important in conditions like sepsis.

When administered as a treatment, Protein C concentrate helps restore these functions in patients who have a deficiency or in conditions where these processes are impaired.

Forms of Protein C

Protein C is available in two main forms:

  1. Protein C Concentrate: This is the inactive form of the protein, which is activated by the body when needed.
  2. Activated Protein C (APC): This is the active form of the protein, ready to work immediately when administered.

How Protein C is Administered

Protein C is typically administered through intravenous (IV) injection or infusion. The dosage and duration of treatment can vary depending on the condition being treated and the patient's response:

  • For congenital Protein C deficiency, it may be given as needed or as long-term supplementation.
  • In sepsis treatment, it's often given as a continuous infusion for 72-96 hours.
  • For acute stroke, it has been studied as a single dose given within 9 hours of symptom onset.

Effectiveness of Protein C

The effectiveness of Protein C concentrate has been demonstrated in several studies:

  • In congenital Protein C deficiency, it has been shown to effectively treat and prevent episodes of purpura fulminans (a severe blood clotting disorder) and other thromboembolic events (blood clots).
  • In sepsis, it has shown potential to improve blood flow in small blood vessels and organ function.
  • In acute pancreatitis, it may help reduce organ dysfunction.
  • In acute stroke, it's being studied for its potential to reduce brain damage.

Safety and Side Effects

Protein C concentrate is generally considered safe, but like all medications, it can have side effects. The most significant concern is the risk of bleeding, which is carefully monitored during treatment.

Other potential side effects may include allergic reactions. However, severe allergic complications appear to be rare.

Ongoing Research

Research on Protein C is ongoing, with several clinical trials exploring its use in various conditions:

  • A study in Japan is evaluating the long-term safety and effectiveness of Protein C concentrate in patients with congenital Protein C deficiency.
  • Researchers are investigating its potential benefits in sepsis, acute pancreatitis, and acute stroke.

These studies aim to better understand how Protein C can be used to improve patient outcomes in these serious conditions.

Questions people often ask

Conditions where Protein C is being studied

Each condition opens its own overview and trial list

Trials with Protein C

Recruiting trials first

See all 4 →
Quick filters
  • Participants:Adults
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).